Now accepting patients in South Florida. Book your free assessment →
Healing & Repair

BPC-157: Evidence, Uses and Risks

Also known as: Body Protection Compound-157, PL 14736, Bepecin

BPC-157 is an investigational tissue-repair peptide. Human evidence is very limited and does not establish reliable healing benefits or long-term safety.

E
Written by
Health & Wellness Writer · Editorial Team, Strong Health
D
Medically reviewed by
M.D., Board-Certified Psychiatrist · Medical Reviewer, Strong Health
Published: July 18, 2026 Updated: November 3, 2026 · Editorial Standards

Key takeaways

  • BPC-157 is a 15-amino-acid peptide derived from a protein in human gastric juice, studied for tendon, ligament, muscle and gut healing. [1]
  • Published preclinical healing findings do not establish human efficacy; the review describes predominantly small rodent studies. [1]
  • Its best-characterized action is angiogenesis plus growth-factor signaling at the injury site; tendon fibroblasts migrate and survive better in culture. [2][3]
  • A 2026 systematic review found only three human studies (30 patients), all of poor quality, and rated the evidence very low certainty. [4]
  • Compounding access is substance- and route-specific; enforcement discretion does not establish FDA approval, safety or efficacy. [90][91]

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide made up of 15 amino acids. Its sequence is derived from a protein found naturally in human gastric juice, where the parent compound is thought to contribute to the stomach lining's remarkable ability to protect and repair itself.

In research and clinical settings, BPC-157 is studied as a body-wide healing agent. Unlike growth-hormone peptides, it has no direct hormonal or androgenic activity; it works locally on tissue-repair and vascular pathways. It is not an FDA-approved drug; in the United States any proposed compounding requires a separate, current substance-specific assessment. [90][91]

What does the evidence show for BPC-157?

The great majority of BPC-157 evidence comes from animal models, where results have been consistent and striking: accelerated healing of transected Achilles tendon, medial collateral ligament, and muscle, plus protection of the gastrointestinal tract against a range of insults [1][2].

Mechanistic studies attribute these effects to angiogenesis and growth-factor upregulation at the injury site [2][3]. What is missing is high-quality human data: as of this writing there are no large, published randomized controlled trials in people, so BPC-157 sits in the category of a promising compound with strong preclinical support and limited clinical validation.

We present this honestly to every patient. The limited human evidence does not establish a favorable safety profile or reliable treatment benefit. Mechanistic rationale is a reason for research, not a substitute for controlled trials.

BPC-157 evidence by study type
Evidence Model Finding Source
Tendon healingRat Achilles transectionFaster healing, better biomechanics and collagen organization[1]
Tendon cellsRat tendon fibroblast cultureMore outgrowth, migration and survival via FAK–paxillin signaling[2]
Gut and soft tissueRodent modelsProtection and healing across tissues; angiogenic mechanism[3]
Human evidenceSystematic review, 3 studies, n = 30Poor methodological quality; very low certainty[4]

However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans.

Gwyer D, Wragg NM, Wilson SL — Cell and Tissue Research, 2019

What are the risks and unknowns for BPC-157?

BPC-157 is not an FDA-approved medication. Compounding status depends on the exact substance, route and current policy. The October 2026 HHS policy describes conditional enforcement discretion for six specified substances under section 503A; it is not FDA approval or a finding of clinical effectiveness. It does not establish blanket access through 503B outsourcing facilities. [90][91]

Human safety data for BPC-157 are limited. Animal tolerability, small studies and anecdotal reports cannot establish the frequency of adverse effects or long-term safety for a proposed treatment.

Risks also depend on formulation, dose, route, interactions and product quality. A compounded preparation is not FDA-approved; pharmacy sourcing does not remove the uncertainties about the molecule itself. Review existing medicines and health conditions with a qualified clinician. [90]

Side effects and safety considerations

  • ·Transient injection-site irritation, redness, or soreness
  • ·Occasional mild nausea or lightheadedness
  • ·Fatigue in the first days of a course (uncommon)

Who should not use it

  • ·Active malignancy (angiogenic activity is a theoretical concern)
  • ·Pregnancy or breastfeeding
  • ·Known hypersensitivity to the compound

How does BPC-157 work?

BPC-157's best-characterized action is angiogenesis, the formation of new blood vessels at an injury site. Better blood supply delivers oxygen, nutrients, and repair cells to damaged tendon, ligament, and muscle, which are otherwise slow to heal because of their limited native blood flow.

Preclinical work also points to upregulation of growth-factor receptors (notably the VEGFR2 pathway), modulation of nitric-oxide signaling, and effects on fibroblast migration and collagen organization. Together these mechanisms are proposed to accelerate the remodeling phase of healing and to exert a protective, anti-inflammatory effect on the gut lining.

Which uses are discussed for BPC-157?

Tendon & ligament injury

The most common reason patients ask about BPC-157: recovery from strains, partial tears, and chronic tendinopathy that has plateaued with rest and physical therapy.

Muscle & soft-tissue recovery

Supporting recovery from muscle injury and overuse in active patients, typically alongside a structured rehab program rather than in place of one.

Joint & arthritic pain

Used as part of a joint-support protocol for its proposed anti-inflammatory and tissue-repair effects; frequently paired with TB-500.

Gastrointestinal support

Studied for its protective effect on the gut lining, including in the context of NSAID-related irritation.

What should you know about BPC-157 dosing?

BPC-157 is most often administered by subcutaneous injection near the area of injury, though oral and other routes have been studied. Protocols in clinical use are typically short courses measured in weeks, with the dose expressed in micrograms per kilogram of body weight.

The specific dose, route, frequency, and duration are individualized by the prescribing physician based on the injury, your body weight, and your response, which is why we frame this as clinical context rather than a self-dosing guide. BPC-157 obtained without a prescription (research-only vials, gray-market powders) carries no guarantee of identity, purity, or sterility.

What should you discuss before considering BPC-157?

A discussion about BPC-157 starts with the diagnosis, existing care and the limitations of the human evidence. Ask which outcome was measured in people and whether the studied substance, formulation and route match the proposed product. A consultation does not guarantee a prescription or treatment benefit.

Before any proposed compounded treatment, the prescriber and pharmacist must check current substance-specific requirements, product identity and route. Pharmacy licensing and clinician supervision do not establish FDA approval, effectiveness or long-term safety. Discuss alternatives, monitoring and reasons to stop before making a decision. [90][91]

Discuss BPC-157 evidence and options →

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved medication. Compounding is a separate question, assessed for the specific substance, route and current federal and state requirements. The October 2026 HHS policy addresses only specified substances under conditions; it does not establish that every peptide can be compounded or that a proposed treatment works.

How long does BPC-157 take to work?

Reliable human evidence does not establish a predictable benefit or treatment schedule for every proposed use of BPC-157. A mechanism or a patient testimonial cannot determine how you will respond, and combination protocols add uncertainty. Ask your clinician about the exact evidence, alternatives and monitoring rather than relying on a standard timeline or stack.

Is BPC-157 a steroid or hormone?

No. BPC-157 has no androgenic or direct hormonal activity. It acts locally on tissue-repair and blood-vessel pathways, which is why it is used for recovery rather than for building muscle the way anabolic hormones do. It can be combined with other protocols under physician oversight.

Can BPC-157 be combined with TB-500?

Reliable human evidence does not establish a predictable benefit or treatment schedule for every proposed use of BPC-157. A mechanism or a patient testimonial cannot determine how you will respond, and combination protocols add uncertainty. Ask your clinician about the exact evidence, alternatives and monitoring rather than relying on a standard timeline or stack.

Is BPC-157 safe?

Safety has not been established for every proposed use of BPC-157. Small studies, animal findings and few reported side effects cannot rule out uncommon or long-term harms. Product quality, route, other medicines and individual health conditions also matter. Physician supervision and pharmacy sourcing do not replace adequate human safety evidence.

References & sources

  1. [90] FDA. Human Drug Compounding. Accessed November 3, 2026. View source →
  2. [91] HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026; accessed November 3, 2026. View source →
  3. [1] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. View source →
  4. [2] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View source →
  5. [3] Seiwerth S, et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing and cytoprotection. Curr Pharm Des. 2018. View source →
  6. [4] Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). View source →
👉 Book a Free Peptide Therapy Assessment